A phase II neoadjuvant study will evaluate ARV-471 or anastrozole, a nonsteroidal aromatase inhibitor, in post-menopausal women with ER+/HER2- localized breast cancer amenable to surgical resection to address the biological activity of respective compound (NCT05549505). This evidence concerns the gene ESR1 and breast cancer.